Cystitis

Tarafenacin (SVT-40776) D-tartrate is an orally active, selective M3 muscarinic receptor (M3 muscarinic receptor) antagonist with 203-fold selectivity over the M2 muscarinic receptor. Tarafenacin D-tartrate does not affect atrial contraction, arterial blood pressure or arterial pressure at high doses. Tarafenacin D-tartrate can be used in the research of overactive bladder.

Tarafenacin (SVT-40776) is an orally active, selective M3 muscarinic receptor (M3 muscarinic receptor) antagonist with 203-fold selectivity over the M2 muscarinic receptor. Tarafenacin does not affect atrial contraction, arterial blood pressure or arterial pressure at high doses. Tarafenacin can be used in the research of overactive bladder.

GPR84 antagonist 9 is an orally active GPR84 antagonist with an IC₅₀ value of 12 nM. By antagonizing the GPR84 receptor, GPR84 antagonist 9 blocks immune cell migration, M1 polarization, and the release of inflammatory factors (IL1β/TNFα) induced by medium-chain free fatty acids (MCFFAs) and other substances, thereby comprehensively inhibiting inflammatory and fibrotic responses. GPR84 antagonist 9 can be used in the research of inflammation-driven pain disorders, including neuropathic pain disorders, Fabry disease, gout, and bladder pain syndrome.